Genmab — Januar 2026
-
Teclistamab Monotherapy Improves OS and PFS Over SOC in Relapsed/Refractory Multiple Myeloma -reducing disease progression or death risk by 71% and death risk by 40%. -the Independent Data Monitoring Committee recommended unblinding the trial based on the strength of the results.
https://www.onclive.com/view/teclistamab-monotherapy-improves-os-and-pfs-over-soc-in-relapsed-refractory-multiple-myeloma -
Godmorgen
-
Genmab viser igen gode takter med kræftmiddel i fase 3-studie https://proinvestor.com/investornyt/1404446/genmab-viser-igen-gode-takter-med-kraeftmiddel-i-fase-3-studie
-
How AbbVie’s epcoritamab reshapes the competitive calculus in relapsed diffuse large B-cell lymphoma https://pharmadevicenews.com/how-abbvies-epcoritamab-reshapes-the-competitive-calculus-in-relapsed-diffuse-large-b-cell-lymphoma/
-
Matt Phipps
William Blair
Buy Reiterated https://longbridge.com/en/news/272881086?channel=WHAB0002 -
Vi er ned med 4-5%
-
*nede
-
SHB: Överdriven marknadsreaktion på Genmabs Epkinly-studie https://borsvarlden.com/artiklar/shb-overdriven-marknadsreaktion-pa-genmabs-epkinly-studie
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind